CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a discovery-stage therapeutics and technology company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, presented new data today at the 2021 Neuroimmunology Drug Development (NIDD) Summit. Chief Scientific Officer Graham Dempsey, Ph.D., presented an overview of the company’s platform for therapeutic discovery in CNS-based disorders and detailed an application of the platform in chronic pain conditions associated with inflammatory mediators. Included in the presentation were data demonstrating the platform’s ability to quantitively characterize the shifting relative contributions of NaV1.7 and NaV1.8 sodium channels in the pain sensitization of neurons following inflammatory challenge and various levels of optical stimulus. This capability provides greater context for both understanding pain pathophysiology and for the development of subtype-specific and dual-targeting therapeutic strategies. Q-State is currently applying these unique insights to generate more precise and more effective therapeutic analgesics.
About Q-State Biosciences
Q-State Biosciences is a technology-derived medicines company based in Cambridge, Massachusetts. We integrate advanced human neuronal models, proprietary determinative measurement engineering and powerful AI/machine learning to discover and develop novel therapeutics for epilepsy, pain, and other disorders of the CNS. For more information, please visit www.qstatebio.com.